Surmodics' FY24 revenue projection is slightly above the estimated $115.52M, which could be seen as a positive sign. However, the projected decrease from FY23 might raise concerns about the company's growth prospects, leading to potential uncertainty among investors. This could have a neutral impact on the stock price in the short term as the market weighs the positive and negative aspects of the forecast.